title: Development of extended zero-order release gliclazide tablets by central composite design.
abstract: The purpose of this study was to develop an extended release tablet formulation containing gliclazide as a model drug by optimization technique. A central composite design was employed with pH-dependent matrix forming polymers like keltone-HVCR (X1) and eudragit-EPO (X2) as independent variables. Five dependent variables were considered: hardness, percent drug release after 1 hr, percent drug release after 6 hr, diffusion exponent and time required for 50% of drug release. Response surface methodology and multiple response optimization utilizing a quadratic polynomial equation were used to obtain an optimal formulation. The results indicate that Factor X1 along its interaction with Factor X2 was found to be significantly affecting the studied response variables. An optimized formulation, containing 8 mg of keltone-HVCR and 14.10mg of eudragit-EPO, provides a sufficient hardness (> 4.5 kg/cm2) and optimal release properties. The desirability function was used to optimize the response variables, each having a different target and the observed responses were highly agreed with experimental values. The release kinetics of gliclazide from optimized formulation followed zero-order release pattern. The dissolution profiles of optimized formulation before and after stability studies were evaluated by using similarity factor (f2) and were found to be similar. The results demonstrate the feasibility of the model in the development of extended release dosage form.
authors.affiliation: Department of Pharmaceutics, Al-Ameen College of Pharmacy, Bangalore, India. pvldss@yahoo.com
authors.forename: P
authors.initials: P
authors.lastname: Vijayalakshmi
authors.forename: V Kusum
authors.initials: VK
authors.lastname: Devi
authors.forename: C
authors.initials: C
authors.lastname: Narendra
authors.forename: S
authors.initials: S
authors.lastname: Srinagesh
mesh_terms: D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004355:Drug Stability; D005907:Gliclazide / Q000008:administration & dosage / Q000737:chemistry*; D006244:Hardness; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D011108:Polymers; D012995:Solubility; D013499:Surface Properties; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D011108:Polymers; D013607:Tablets; D005907:Gliclazide